Biosecurity Modernization and Innovation Act of 2026
Introduced January 29, 2026 · Last action January 29, 2026
Plain English Summary
This bill requires the Department of Commerce to create federal regulations for companies that synthesize or sell DNA/RNA (nucleic acids) and equipment to do so, including screening of customer orders and customer identity verification to prevent creation of dangerous pathogens. It also directs Commerce to establish a testing environment for biotechnology governance innovations and requires the White House Office of Science and Technology Policy to assess and streamline how biosecurity oversight is divided among federal agencies.
Who benefits
Legitimate nucleic acid synthesis companies, academic institutions, and biotech firms that meet compliance standards and can demonstrate customer legitimacy—they gain access to a regulated market protected from non-compliant competitors. Large research universities and accredited institutions benefit from expedited review processes. Biotechnology companies operating in the U.S. benefit from clearer, unified federal oversight rather than fragmented agency guidance. Gene synthesis screening companies that provide order screening and customer verification services will gain a regulated market as mandatory compliance creates demand for their tools and services. The U.S. biotechnology industry broadly benefits from reduced biosecurity risk to its reputation and continued global competitiveness. The federal government gains clarity on which synthesis providers are operating legitimately.
Who pays / loses
Gene synthesis companies (small to mid-sized firms especially) that lack existing customer verification and order-screening infrastructure face compliance costs and operational burden to implement new screening protocols and undergo conformity audits. International nucleic acid synthesis providers and equipment manufacturers selling into the U.S. must comply or lose U.S. customers. Companies unable to implement sophisticated screening systems or that cannot pass conformity assessment audits will lose market access. Researchers and biotech companies in the U.S. face additional time and documentation requirements when ordering synthesis products, particularly those without institutional affiliation or established legitimacy records. Non-U.S. synthesis providers face barriers to the U.S. market if they do not establish U.S.-compliant operations. Individuals and entities attempting to order potentially dangerous sequences will face barriers due to customer identity verification requirements.
Funding & Lobbying Interests
Companies that provide gene synthesis screening software, order-detection platforms, and customer verification tools will benefit from mandatory compliance demand—firms like Ginkgo Bioworks and Zymergen have direct interest in standardized screening. Large biotech firms (Moderna, Pfizer, Merck) and academic research institutions benefit from regulatory clarity and competitive advantages over non-compliant competitors. U.S.-based nucleic acid synthesis companies (e.g., those in the commercial synthetic biology space) benefit from barriers to international competitors. The sponsors—Sen. Tom Cotton (R-AR) and Sen. Amy Klobuchar (D-MN)—bring bipartisan consensus on biosecurity. No specific campaign finance data was provided in the bill text, but industries with financial stakes include: nucleic acid synthesis providers, benchtop synthesizer manufacturers, biotech firms requiring synthesis inputs, academic research institutions, biotechnology governance consulting firms, and companies providing compliance and auditing services.
Political Impact
Affected Groups
Gene synthesis companies and their employees across the United States (estimated hundreds of firms ranging from startups to large biotech subsidiaries). Accredited research universities and institutions—approximately 4,000+ institutions in the U.S. conducting biomedical research. Biotech industry workers and researchers who order synthesis products as part of their work. Small biotechnology firms and startups (1,000+) that may lack resources for sophisticated compliance infrastructure. Academic researchers at non-accredited or smaller institutions who face more stringent verification requirements. International nucleic acid synthesis providers and their U.S. customers seeking to import or use non-U.S. providers. Federal researchers and contractors who can only purchase from compliant providers.
Political Subtext
Proponents argue this bill closes a critical biosecurity gap: gene synthesis technology has become accessible and sophisticated enough that bad actors could order sequences to manufacture dangerous pathogens, and current voluntary federal screening is fragmented and outdated. The bipartisan support from Cotton (security-focused Republican) and Klobuchar (innovation-focused Democrat) reflects consensus that biosecurity screening is necessary. Supporters cite GAO reports and the National Security Commission for Emerging Biotechnology identifying gaps in federal oversight. Critics (implied by the bill's own balancing language) worry that mandatory screening will burden legitimate researchers and companies with compliance costs, slow innovation, and disadvantage U.S. firms against international competitors who face no such requirements—the bill attempts to mitigate this with expedited review for established institutions and exemptions for non-hazardous sequences. The bill explicitly frames biosecurity as compatible with U.S. biotechnology competitiveness, not opposed to it. Non-partisan biotechnology governance experts recognize that gene synthesis screening is now standard practice in the industry (companies like Ginkgo Bioworks already conduct it voluntarily), suggesting the bill likely codifies and standardizes what responsible firms already do.
Real-World Stakes
If this passes, all U.S. nucleic acid synthesis companies and equipment manufacturers will be required to implement customer verification and order screening by 2027, making the U.S. the first country with mandatory federal synthesis security regulations. This follows the voluntary International Committee on Synthetic Biology screening consensus (adopted 2021) but makes it enforceable law. Companies that fail to comply face civil penalties up to $750,000 and loss of access to federal contractors and grant recipients—a major market segment. The federal workforce and academic research institutions will be limited to purchasing from compliant providers, creating market pressure for compliance. Precedent: the EU implemented non-binding synthesis security guidelines; the bill goes further with binding requirements and enforcement. Academic research could face delays if sequence-screening protocols are overly conservative. International competitors without equivalent regulations may gain cost advantages, though the federal contracting restriction mitigates this for U.S.-focused sales. The bill's sandbox environment and governance review (Sections 5-6) signal intent to avoid stifling innovation, but real-world impact depends on how strictly the Commerce Secretary interprets 'sequences of concern' and how transparent the screening criteria are to researchers. Historical precedent: the 2005 Select agent regulations for dangerous biological agents created substantial compliance burdens on legitimate research but have been credited with reducing dual-use risks.
Sponsor
Sponsor information not available.
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
No campaign finance data available yet.
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.